Zurich-based Rivia has launched Data Findings, an AI-powered module that automatically checks clinical trial data, flags issues early and tracks them to resolution. It is an add-on to Rivia Core, which unifies trial data from different systems and vendors. An agentic rule builder lets teams create complex checks from plain-language instructions, without programming. Checks run continuously as data changes, rather than waiting for final clean-up. UK biotech Scancell, the first adopter, expects to cut end-of-study data cleaning from eight weeks to two. It could bring forward database lock by six weeks. Tufts Center for the Study of Drug Development estimates delays cost about $800,000 in lost sales per day. In March 2026, Rivia closed a $15 million (€13 million) Series A round led by Earlybird Venture Capital.

Zurich-based Rivia has raised €13 million in Series A funding led by Earlybird, with participation from Defiant, Speedinvest, Amino Collective and Nina Capital. The startup develops AI-driven analytics and data infrastructure for biotechnology clinical trials. Founded in 2022, Rivia has built what it calls an intelligence layer for clinical trials, integrating heterogeneous data files in real-time and applying scientific logic through reusable configurations. The company is launching AI agents, including Spark, which converts natural language into clinical visualisations, and aims to reduce clinical trial costs by up to 50%. Rivia currently supports 40 clinical trials globally across the US and Europe, achieving fourfold ARR growth in 2025. The funding will support team expansion, product development and US market growth.